Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2024 · 10-Q
Revenue—
Net Income-$501.69K-$501.69KN/M vs Q2 2023 EPS Diluted$0.00$0.00— vs Q2 2023 Operating Income-$585,147N/M Operating Cash Flowderived-$583,079N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end